Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bliss GVS PharmaBOM:506197 +1.89%58 Interest Coverage is 114.71 as of Jun. 2026, which is 463% above its 10-year median of 20.36. GuruFocus rates BOM:506197 with a GF Score™ of 58/100 and a GF Value™ of ₹170.36 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 685 Drug Manufacturers companies, Bliss GVS Pharma ranks better than 58.98% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Bliss GVS Pharma's
Operating Income
for the
three
months ended in Jun. 2026 was ₹665 Mil. Bliss GVS Pharma's Interest Expense for the
three
months ended in Jun. 2026 was ₹-6 Mil.
Bliss GVS Pharma's interest coverage for the quarter that ended in Jun. 2026 was 114.71.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Bliss GVS Pharma's Interest Coverage or its related term are showing as below:
BOM:506197'
s Interest Coverage Range Over the Past 10 Years
Min: 8.18 Med: 20.36 Max: 42.88
Current: 21.39
BOM:506197's Interest Coverage is ranked better than 58.98% of 685
companies
in the Drug Manufacturers industry
Industry Median: 13.55
vs BOM:506197: 21.39
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Bliss GVS Pharma Interest Coverage Related Terms
Bliss GVS Pharma Interest Coverage Historical Data
* Premium members only.
The historical data trend for Bliss GVS Pharma's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Bliss GVS Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bliss GVS Pharma Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bliss GVS Pharma's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Bliss GVS Pharma's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bliss GVS Pharma (BOM:506197) has a Interest Coverage of 114.71 as of Jun. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Bliss GVS Pharma and its competitors. This is 463% above median its historical median of 20.36. Over the past decade, Bliss GVS Pharma's Interest Coverage has ranged from 8.18 to 42.88. According to the industry distribution chart, Bliss GVS Pharma ranks #281 out of 685 companies in the Drug Manufacturers industry, placing it in the top 41%.
Is Bliss GVS Pharma's Interest Coverage too high?
Bliss GVS Pharma's current Interest Coverage of 114.71 is 463% above median its 10-year median of 20.36. Over the past 10 years, this metric has ranged from a low of 8.18 to a high of 42.88. The Drug Manufacturers industry median Interest Coverage is 13.55. Bliss GVS Pharma's value of 114.71 is 746.6% above this industry median. Based on the distribution chart, Bliss GVS Pharma ranks #281 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bliss GVS Pharma has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bliss GVS Pharma's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Bliss GVS Pharma ranks #281 out of 685 companies for Interest Coverage. This puts Bliss GVS Pharma in the upper half of its industry. The industry median Interest Coverage is 13.55. Bliss GVS Pharma's value of 114.71 is 746.6% above this benchmark. Historically, Bliss GVS Pharma's own Interest Coverage has ranged from 8.18 to 42.88 over the past decade. While the company's 10-year median is 20.36 vs. the industry median of 13.55, Bliss GVS Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 13.55, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bliss GVS Pharma's current Interest Coverage of 114.71 is 746.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Bliss GVS Pharma and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bliss GVS Pharma's current Interest Coverage is 114.71, which is 463% above median its own 10-year median of 20.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bliss GVS Pharma stock overvalued right now?
Based on GuruFocus' analysis, Bliss GVS Pharma (BOM:506197) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹170.36, compared to a current price of ₹570.80 — trading 235.1% above its estimated fair value. The current Interest Coverage is 114.71, which is 463% above median its 10-year median of 20.36 and 746.6% above the Drug Manufacturers industry median of 13.55. Bliss GVS Pharma's overall GF Score™ is 58/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Bliss GVS Pharma (BOM:506197), the current Interest Coverage is 114.71 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bliss GVS Pharma (BOM:506197) Overvalued in 2026?
Based on GuruFocus' analysis, Bliss GVS Pharma stock appears to be overvalued.
The current stock price of ₹570.80 is trading 235.1% above its estimated GF Value™ of ₹170.36.
GuruFocus considers Bliss GVS Pharma to be Significantly Overvalued.
Key valuation signals for BOM:506197:
Interest Coverage: 114.71 (463% above median its 10-year median of 20.36)
GF Value™: ₹170.36 vs. price of ₹570.80 (235.1% above fair value)
Industry Position: 746.6% above the Drug Manufacturers median (#281 of 685)
No single metric tells the full story. See the BOM:506197 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bliss GVS Pharma Ltd is an India-based company engaged in the manufacturing, marketing, trading, and export of pharmaceutical products. Some of its brands include Lonart, P-Alaxin, Funbact, and Lofnac, and others. It offers pharma products including tablets, suspensions, suppositories, and injections. The majority of its revenue is derived from Exports.
58GF Score
Get the complete analysis for BOM:506197
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506197 has been successfully added to your 
